1. Slamon DJ, Neven P, Chia S, Fasching PA, De Laurentiis M, Im SA, et al. Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med. 2020 Feb;382(6):514–24.
2. Booth CM, Tannock IF. Randomised controlled trials and population-based observational research: partners in the evolution of medical evidence. Br J Cancer. 2014 Feb;110(3):551–5.
3. Foukakis T, Fornander T, Lekberg T, Hellborg H, Adolfsson J, Bergh J. Age-specific trends of survival in metastatic breast cancer: 26 years longitudinal data from a population-based cancer registry in Stockholm, Sweden. Breast Cancer Res Treat. 2011 Nov;130(2):553–60.
4. Cardoso F, Di LA, Lohrisch C, Bernard C, Ferreira F, Piccart MJ. Second and subsequent lines of chemotherapy for metastatic breast cancer: what did we learn in the last two decades?. Ann Oncol. 2002 Feb;13(2):197–207.
5. Yamamoto N, Watanabe T, Katsumata N, Omuro Y, Ando M, Fukuda H, et al. Construction and validation of a practical prognostic index for patients with metastatic breast cancer. J Clin Oncol. 1998 Jul;16(7):2401–8.